Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation.
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision nanomedicines enabled by our hydroxyl dendrimer (HD) technology to treat unmet medical needs in ophthalmology, neurology, and inflammatory diseases. Our precision nanomedicines are selectively taken up only by inflamed tissues, allowing us to treat disease with unprecedented precision.
We have designed a potent anti-angiogenic nanomedicine that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages, and retinal pigment epithelial cells in the eye
We are developing a biomarker for neuroinflammation to quantitatively study penetration of the blood-brain barrier and measure treatment responses to our nanomedicines
Our novel nanomedicine selectively targets regions of inflammation and has the potential to modulate the activity of cells that direct inflammation in multiple diseases
Ashvattha receives additional financing up to $50 million with new lead investor Tribe Capital and existing investors led by Natural Capital Ashvattha’s at-home monthly subcutaneously-administered
Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the
Presentations highlight the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE